Bleakley Financial Group LLC decreased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 72.7% during the first quarter, HoldingsChannel.com reports. The fund owned 10,794 shares of the medical research company’s stock after selling 28,787 shares during the period. Bleakley Financial Group LLC’s holdings in Edwards Lifesciences were worth $864,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $26,000. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the first quarter worth $25,000. Kemnay Advisory Services Inc. bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $27,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC bought a new position in Edwards Lifesciences during the fourth quarter worth about $28,000. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance
NYSE:EW opened at $85.72 on Friday. The stock has a market capitalization of $49.36 billion, a P/E ratio of 45.60, a price-to-earnings-growth ratio of 2.20 and a beta of 0.86. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The firm has a 50 day moving average of $87.34 and a 200-day moving average of $83.94.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on EW. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research note on Wednesday, April 1st. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. TD Cowen reiterated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Finally, Evercore reissued an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.95.
Get Our Latest Stock Report on EW
Insider Activity
In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is owned by corporate insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
